Octagam 10%
Sponsors
Universitair Medisch Centrum Utrecht, Octapharma, Sutter Health
Conditions
Alzheimer's DiseaseCovid-19DermatomyositisImmune Thrombocytopenic PurpuraImmunologic Deficiency SyndromesMild Cognitive ImpairmentPrimary antibody deficiency:
- Unclassified antibody deficiency (unPAD)
- IgA deficiency
- Specific polysaccharide antibody deficiency (SPAD)
- IgG subclass deficiency (IgSD)
- Common variable immunodeficiency (CVID)
- Agammaglobulinemia (X-linked or otherwise)
Phase 2
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
CompletedNCT00812565
Start: 2009-02-28End: 2010-09-30Updated: 2014-05-05
Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease
CompletedNCT03319810
Start: 2018-01-04End: 2018-07-19Updated: 2019-06-25
Phase 3
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
CompletedNCT00426270
Start: 2006-06-30End: 2008-09-30Updated: 2014-08-01
Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
TerminatedNCT00811174
Start: 2009-01-31End: 2010-09-30Updated: 2017-07-14
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
CompletedNCT02728752
Start: 2017-02-27End: 2019-11-05Updated: 2021-12-23
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
CompletedNCT04400058
Start: 2020-06-01End: 2022-02-01Updated: 2024-01-18
Influencing Progression of Airway Disease in Primary Antibody Deficiency
Not yet recruitingCTIS2024-513124-41-00
Target: 100Updated: 2024-07-12